Markets:

Overview

News

Currencies

International

Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

189.51 -0.69 (-0.36%)

Streaming Delayed Price Updated: 10:06 AM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Demystifying Ligand Pharmaceuticals: Insights From 10 Analyst Reviews ↗

December 11, 2024

Via Benzinga

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

December 10, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. ↗

December 09, 2024

The companies held competing events on Sunday to discuss their multiple myeloma treatments.

Via Investor's Business Daily

A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticals ↗

November 08, 2024

Via Benzinga

Assessing Ligand Pharmaceuticals: Insights From 7 Financial Analysts ↗

October 21, 2024

Via Benzinga

The Latest Analyst Ratings For Ligand Pharmaceuticals ↗

October 03, 2024

Via Benzinga

Ligand to Present at Stifel 2024 Healthcare Conference

November 14, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

November 07, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

November 01, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

October 23, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Looking Into Ligand Pharmaceuticals's Recent Short Interest ↗

August 16, 2024

Via Benzinga

Assessing Ligand Pharmaceuticals: Insights From 6 Financial Analysts ↗

July 30, 2024

Via Benzinga

What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals ↗

June 28, 2024

Via Benzinga

Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know ↗

October 21, 2024

Via Benzinga

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

October 17, 2024

Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment...

From Palvella Therapeutics

Via GlobeNewswire

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

September 06, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

August 20, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review ↗

August 09, 2024

After Monday's panicked global sell-off, markets have calmed down.

Via Investor's Business Daily

LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗

August 06, 2024

LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts ↗

August 06, 2024

Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped.

Via Investor's Business Daily

Ligand Reports Second Quarter 2024 Financial Results

August 06, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024

July 23, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

5 Best Short-Term Stocks to Consider Investing In

July 10, 2024

Looking for the best short-term stocks? Explore our top picks and learn how to navigate the risks and opportunities in fast-paced stock trading.

Via MarketBeat

Ligand to Acquire APEIRON Biologics AG for $100 Million

July 08, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Lifecore Biomedical Announces Cooperation Agreement with 22NW

July 01, 2024

Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board

From Lifecore Biomedical, Inc.

Via GlobeNewswire

Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years

June 27, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults

June 18, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand to Participate in Upcoming Investor Conferences

May 23, 2024

From Ligand Pharmaceuticals Incorporated

Via Business Wire

3 Magnificent Growth Stocks to Buy Hand Over Fist ↗

May 22, 2024

Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.

Via The Motley Fool

Topics Economy

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.